GANYMED Pharmaceuticals AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GANYMED Pharmaceuticals AG - overview
Established
2001
Location
Mainz, -, Germany
Primary Industry
Biotechnology
About
GANYMED Pharmaceuticals AG is engaged in the development and manufacturing of innovative pharmaceuticals targeted at treating various diseases, focusing on delivering effective solutions to diverse healthcare needs. GANYMED Pharmaceuticals AG, founded in 2001 in Mainz, Germany, specializes in pharmaceutical development. The company has undergone no major strategic pivots or changes in business operations and has not reported any subsidiaries. Christoph Huber, the founder of GANYMED, has been instrumental in its establishment.
The company has completed a total of 9 deals, with its most recent deal on October 28, 2016, involving a TRADE SALE to Astellas Pharma Inc. for EUR 422. 00 mn, marking the total amount raised to EUR 422. 00 mn.
GANYMED Pharmaceuticals focuses on developing a range of pharmaceuticals, including tablets, capsules, injections, creams, and syrups, aimed at treating a variety of health issues. Their products are distributed to hospitals, healthcare providers, and retail pharmacies, thereby ensuring patients have access to necessary treatments for chronic and acute conditions. In 2015, GANYMED Pharmaceuticals reported a revenue of EUR 246,703. 40, while their EBITDA for 2016 was EUR -38,581,545.
70, reflecting the financial dynamics of the company during that period. Following the TRADE SALE in October 2016 to Astellas Pharma, GANYMED Pharmaceuticals is poised for growth by focusing on the development of new pharmaceutical products and expanding into new geographic markets. Specific regions targeted for expansion have not been detailed, but the company aims to leverage recent funding to bolster its research and development initiatives, ensuring alignment with evolving healthcare demands.
Current Investors
First Capital , Nextech, Sud Beteiligungen
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.ganymed-pharmaceuticals.de
Company Stage
Acquired
Total Amount Raised
Subscriber access only
GANYMED Pharmaceuticals AG - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 149,500 | 3,087,398.7 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | 1965.1% | - | - | - |
| EBITDA (USD) | (16,124,452.7) | (16,973,670.6) | (18,110,187.9) | (16,739,615.9) | - | - | - |
| Operating Income (USD) | (16,521,697.2) | (17,403,420.9) | (18,510,997.6) | (17,128,890.6) | - | - | - |
| Operating Margin | - | - | (12381.9%) | (554.8%) | - | - | - |
| % EBITDA Margin | - | - | (12113.8%) | (542.2%) | - | - | - |
| NET Income (USD) | (16,205,636) | (17,231,080.9) | (18,425,925.2) | (17,099,381.1) | - | - | - |
| % Net Margin | - | - | (12325.0%) | (553.8%) | - | - | - |
GANYMED Pharmaceuticals AG - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.